PsychopharmacologyOctober 27, 2025Nina Gregoire, Ethan Klukas, Kimberley Kaseweter et al.
Ketamine-assisted therapy is emerging as a fast-acting intervention for treatment-resistant depression and anxiety. However, individual response to treatment varies, and little is known about how personality traits and trauma history influence outcomes. This study investigated whether distinct personality profiles emerge in a real-world sample of patients undergoing ketamine therapy and...
It is 60 years since ketamine was first tested in humans as an alternative but safer anaesthetic to PCP (phencyclidine) (Corssen and Domino 1966). It became widely used as the “buddy drug” for combatants in the Vietnam War: because of its great safety margin, it could be injected into wounded personnel by their buddies to relieve pain before the arrival of the medical team. Because of...
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including existential distress, loss of meaning, and emotional pain. Ketamine-assisted psychotherapy (KAP) has emerged as a promising intervention for alleviating such complex forms of suffering, yet models specifically tailored to palliative populations...
Glutamatergic abnormalities in several brain regions, including the ventromedial orbitofrontal cortex (vmOFC) and prefrontal cortex (vmPFC), have been implicated in the pathophysiology of obsessive-compulsive disorder (OCD). (R, S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, and enantiopure (S)-ketamine may have therapeutic effects in patients and animal models of OCD....
Journal of Clinical MedicineOctober 24, 2025Adriano Dos-Santos, Lucas Porto Fernandes Dos Santos, Gabriela Da Silva-Santos et al.
Background/Objectives: Ketamine, widely used for its anesthetic and analgesic properties, has been linked to cardiotoxic effects, particularly with chronic use. Prolonged ketamine exposure may impair cardiovascular function, while aerobic exercise is known to promote protective cardiovascular adaptations. This study aimed to evaluate whether aerobic training can mitigate the deleterious...
More than 280 million individuals worldwide suffer from depression, which is one of the main causes of mental disability. It has multiple subtypes, and conventional treatments have limitations such as slow onset of action, high non-response rate, and numerous side effects. For instance, it takes two to six weeks for selective serotonin reuptake inhibitors (SSRIs) to start working, and about 30%...
Hospital PharmacyOctober 23, 2025Moomal Memon, Rukhsana Gul, Arif Gul et al.1 citation
Depression, projected to be the leading cause of global disability by 2030, affects up to 19.62% of Pakistan's population. Treatment-resistant depression (TRD), characterized by poor response to at least two antidepressants, poses a major clinical challenge. Although interventions like ECT exist, their use is limited by systemic barriers. Esketamine, an NMDA receptor antagonist, offers a...
Key Points Question For inpatients with moderate to severe depression, is repeated intravenous ketamine superior to a psychoactive placebo (midazolam) in reducing depressive symptoms? Findings In this randomized clinical trial, there was no statistically significant difference in the primary outcome, end-of-treatment Montgomery-Åsberg Depression Rating Scale score, between the ketamine and...
OBJECTIVE: Many first responders deal with mental health challenges due to significant work-related stress. Ketamine-assisted therapy (KAT) has been shown to alleviate the symptoms and improve the lives of those living with PTSD. This qualitative case study explores the impacts of KAT on the firefighters beyond the initial alleviation of their PTSD symptoms. METHODS: Six firefighters who were...
CNS DrugsOctober 16, 2025Gisèle Pickering, Véronique Morel, Marion Voute2 citations
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is used off-label in this indication and known for its psychomimetic side-effects. The primary objective of this manuscript is to synthesize the current evidence on ketamine efficacy and safety for chronic refractory pain. Furthermore, it aims to identify...